Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the
“Company”), a biopharmaceutical company dedicated to improving
outcomes for patients with anemia, with an initial focus on
end-stage renal disease (ESRD), today announced that the Company
will sponsor a Triferic (ferric pyrophosphate citrate) Exhibitor
Spotlight presentation at the American Society of Nephrology (ASN)
Kidney Week 2019 Conference in Washington, D.C. on Friday, November
8, 2019.
Presentation Title: |
|
Advances in Hemodialysis-Associated Anemia Management: The Benefits
of Physiologic Iron Replacement Therapy |
|
|
|
Presenter: |
|
Jay B. Wish, MD, Professor of Clinical Medicine, Chief Medical
Officer for Dialysis, Indiana University Health |
|
|
|
Date: |
|
Friday, November 8, 2019 |
|
|
|
Time: |
|
10:00 am – 11:00 am |
|
|
|
Location: |
|
Walter E. Washington Convention Center, Exhibit Hall, Theater #1,
Washington, D.C. |
In today’s clinical practice, it is very common to use
traditional intravenous (IV) iron for repeated replacement of
ongoing iron losses in chronic hemodialysis patients. This practice
results in increased iron stores together with systemic
inflammation.1 The long-range safety of such regular weekly or
monthly traditional intravenous iron dosing regimens is a subject
of some concern and controversy.2 Adverse effects of traditional
intravenous iron may be concealed by their resemblance to common
comorbidities in dialysis patients, such as infection,
cardiovascular disease, and early mortality.3 Evidence of the
negative effects of iron overload and other risks associated with
long-term use of intravenous iron continues to build.3
Unlike traditional IV iron, Triferic replaces dialysis patients’
ongoing iron losses by providing iron with every hemodialysis
treatment that is 100% bioavailable and maintains hemoglobin
without increasing iron stores (ferritin). Triferic has a safety
profile similar to placebo, with few Triferic-related serious
adverse events reported in over 1,000,000 patient
administrations.4,5
“We are very excited to have a clinician of Dr. Wish’s
distinction and expertise speak on behalf of Triferic and believe
this will be an extremely valuable presentation for all
nephrologists who deal with issues around anemia management.
Educating the medical community about the profile of Triferic
through engagement with esteemed medical leaders is critical to get
this important therapeutic to more patients,” said Stuart Paul,
President and Chief Executive Officer of Rockwell Medical.
About Triferic Triferic is the only
FDA-approved therapy indicated to replace iron and maintain
hemoglobin in hemodialysis patients via dialysate during each
dialysis treatment. Triferic delivers approximately 5-7 mg iron
with every hemodialysis treatment to the bone marrow and maintains
hemoglobin without increasing iron stores (ferritin). Unlike
traditional IV iron products, Triferic donates iron immediately and
completely to transferrin (carrier of iron in the body) upon entry
into the blood and is then transported directly to the bone marrow
to be incorporated into hemoglobin, with no increase in ferritin
(stored iron and inflammation) and no reports of anaphylaxis in
over 1,000,000 patient administrations, addressing a significant
medical need in overcoming Functional Iron Deficiency (FID) in ESRD
patients. The Company has developed multiple formulations of
Triferic: (1) FDA-approved Dialysate Triferic; and (2) I.V.
Triferic, for which the Company filed a New Drug Application in May
2019 with a PDUFA date of March 28, 2020. Please visit
www.TRIFERIC.com to view the Triferic mode-of-action (MOA)
video and for more information.
Important Safety Information Serious
hypersensitivity reactions, including anaphylactic-type reactions,
some of which have been life-threatening and fatal, have been
reported in patients receiving parenteral iron products. Patients
may present with shock, clinically significant hypotension, loss of
consciousness, and/or collapse. Monitor patients for signs and
symptoms of hypersensitivity during and after hemodialysis until
clinically stable. Personnel and therapies should be immediately
available for the treatment of serious hypersensitivity reactions.
Hypersensitivity reactions have been reported in 1 (0.3%) of 292
patients receiving TRIFERIC in two randomized clinical trials.
Iron status should be determined on pre-dialysis blood samples.
Post dialysis serum iron parameters may overestimate serum iron and
transferrin saturation.
The most common adverse reactions (≥3% and at least 1% greater
than placebo) in controlled clinical studies include: procedural
hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in
extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back
pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%),
asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula
thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).
For more information, including full prescribing information,
visit: http://www.TRIFERIC.com.
About Rockwell Medical Rockwell Medical is a
biopharmaceutical company dedicated to improving outcomes for
patients with anemia, with an initial focus on end-stage renal
disease (ESRD) and chronic kidney disease (CKD). Rockwell Medical's
exclusive renal drug therapy, Triferic, supports disease management
initiatives to improve the quality of life and care of dialysis
patients and is intended to deliver safe and effective therapy,
while decreasing drug administration costs and improving patient
convenience. The Company has developed multiple formulations
Triferic: (1) Dialysate Triferic; and (2) I.V. Triferic. Dialysate
Triferic is the only FDA-approved therapeutic indicated for iron
replacement and maintenance of hemoglobin in hemodialysis patients.
The Company’s strategy is to bring its therapeutics to market in
the United States and to utilize partners to develop and
commercialize such therapeutics in international markets. Rockwell
Medical is also an established manufacturer, supplier and leader in
delivering high-quality hemodialysis concentrates/dialysates to
dialysis providers and distributors in the U.S. and abroad. Please
visit www.rockwellmed.com for more information.
Forward-Looking Statements Certain statements
in this press release may constitute "forward-looking statements"
within the meaning of the federal securities laws, including, but
not limited to, Rockwell Medical’s intention to bring to market
Triferic, and I.V. Triferic. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "could," "potential," "predict," "forecast," "project,"
"plan," "intend" or similar expressions, or statements regarding
intent, belief, or current expectations, are forward-looking
statements. While Rockwell Medical believes these forward-looking
statements are reasonable, undue reliance should not be placed on
any such forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties (including, without
limitation, those set forth in Rockwell Medical's SEC filings),
many of which are beyond our control and subject to change. Actual
results could be materially different. Risks and uncertainties
include: statements about the timing of data readouts; the timing
for the ruling from CMS; potential market opportunity for I.V.
Triferic, as well as other Rockwell Medical products; pricing and
reimbursement status for I.V. Triferic and other Rockwell Medical
products, including the eligibility of I.V. Triferic for add-on
reimbursement under TDAPA; liquidity and capital resources;
expected duration of Rockwell Medical's existing working capital;
success of our recently announced commercialization of Dialysate
Triferic; and timing and success of our efforts to maintain, grow
and improve the profit margin of the Company’s concentrate
business. Rockwell Medical expressly disclaims any obligation to
update or alter any statements whether as a result of new
information, future events or otherwise, except as required by
law.
Triferic® is a registered trademark of Rockwell Medical,
Inc.
Contact Investor Relations: Lisa M. Wilson,
In-Site Communications, Inc. T: 212-452-2793 E:
lwilson@insitecony.com
Source: Rockwell Medical, Inc.
________________________
- Monitor DP: DOPPS 6. In, 2019
- Macdougall IC, White C, Anker SD, et al. Intravenous Iron in
Patients Undergoing Maintenance Hemodialysis. The New England
Journal of Medicine 2019; 380: 447-458.
- Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock
DG. Time-dependent associations between iron and mortality in
hemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070-3080
- Fishbane SN, Singh AK, Cournoyer SH,et al. Ferric pyrophosphate
citrate (Triferic®) administration via the dialysate
maintains hemoglobin and iron balance in chronic hemodialysis
patients. Nephrol Dial Transplant. 2015;30(12):2019-2026.
- Data on file. Wixom, MI; Rockwell Medical, Inc.
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024